HT

Hiroki Takai

Director, Investment Group, UK Office at Global Brain Corporation

London, England

Overview 

Hiroki Takai is a Biotech VC based in London, with a background in Venture Capital and expertise in areas such as Epigenetics and Cancer Research. As the Director at Global Brain Corporation and having invested in companies like Zafrens and Switch Therapeutics, he has demonstrated a strong track record of successful investments in the biotechnology sector. With experience at Eli Lilly and Company and a diverse educational background including a PhD and MBA, Hiroki Takai has established himself as a key player in the biotech investment landscape, focusing on sectors such as Drug Delivery and Therapeutics.

Work Experience 

GB

Global Brain Corporation

  • Director, Investment Group, UK Office

    2023 - Current

    I am responsible for Life Science investments, including strategy development, investment execution, and growth support. As the first life science investor outside of Japan at Global Brain, I build a tangible network locally and globally and evaluate opportunities in the healthcare sector. I also fundraise and manage the relationship with our Limited Partners.

  • Principal, Investment Group, UK Office

    2022 - 2023

SE

Science Entrepreneur Club

  • TechBio Sector Champion - BioCapital Network

    2025

    The BioCapital Network is an international community of over 380 investors, representing over 230 unique funds and several Angels across 20+ countries, all actively backing life science companies. The community aims to provide a medium for life science investors to network, develop meaningful relationships, share high-quality deal flow, open co-investment opportunities and enable discussions on the latest industry trends and challenges. We focus on the life sciences, broadly encompassing AgriTech, ClimateTech, Digital Health, Life Science Tools and Tech, Medical Devices, TechBio and Therapeutics. Through our online community platform and regular events, I support the growth of our TechBio chapter. Find out more and if you are an active life science investor, you can apply to join here: https://www.science-entrepreneur.com/biocapital-network

EL

Eli Lilly and Company

  • Educational Leave

    2020 - 2022

    London Business School, MBA Class of 2022

  • Senior Associate, Lilly New Ventures

    2021 - 2021

  • Senior Associate, Japan Drug Development and Medical Affairs

    2016 - 2020

Eli Lilly engages in the discovery, development, manufacture, and sale of pharmaceutical products.

Raised $6,500,000.00.

lilly.com
S

SyntheticGestalt

  • Consultant

    2020 - 2022

    My first start-up vibes. Advisory role on R&D from a biochemist perspective.

EI

Economist Intelligence: Clearstate

  • Project Manager

    2021 - 2022

    Forecasting and advisory role at the Economist Group through research and analysis of the Asian Pharmaceutical and CDMO market.

HM

Harvard Medical School

  • Research Fellow

    2015 - 2016

Education 

Investments 

Zafrens

Series A

Total funding: $23M

Switch Therapeutics

Series A

Total funding: $52M

Imophoron

Seed

Total funding: $5M

Heading Health

SAFE

Total funding amount not yet available

Articles About Hiroki

Relevant Websites